Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multicenter, Randomized, Controlled and Double-blind Study of Efficacy and Safety of Endoscopic Gastric Tubulization in Patients With Non-alcoholic Steatohepatitis (NASH-APOLLO). (NASH-APOLLO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03426111
Recruitment Status : Recruiting
First Posted : February 8, 2018
Last Update Posted : December 12, 2018
Sponsor:
Collaborators:
Hospital Universitario Ramon y Cajal
Hospital Universitario Marqués de Valdecilla
Hospitales Universitarios Virgen del Rocío
Information provided by (Responsible Party):
Jose Luis Calleja, Puerta de Hierro University Hospital

Tracking Information
First Submitted Date  ICMJE January 9, 2018
First Posted Date  ICMJE February 8, 2018
Last Update Posted Date December 12, 2018
Actual Study Start Date  ICMJE April 18, 2018
Estimated Primary Completion Date December 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 1, 2018)
To evaluate the efficacy of gastric tubulization + modification in lifestyle for 72 weeks compared to standard treatment / placebo in the resolution of NASH without worsening of fibrosis. [ Time Frame: 72 weeks ]
NASH resolution is defined as the disappearance of ballooning and the disappearance or persistence of minimal lobular inflammation (grade 0 or 1) The worsening of fibrosis is defined as the progression of at least one stage.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03426111 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: February 1, 2018)
  • Number of patients with improvement of fibrosis according to the CRN score NASH. [ Time Frame: 72 weeks ]
    to evaluate other histological changes after 72 weeks of treatment (CRN)
  • Non alcoholic fatty liver disease (NASH) activity score (NAS). [ Time Frame: 72 weeks ]
    Number of patients with improvement in histological scores CRN score on NASH (NAS)
  • steatosis-activity-fibrosis index score (steatosis activity fibrosis, SAF). [ Time Frame: 72 weeks ]
    Number of patients with improvement in the SAF score.
  • Cardiovascular and death events related to the liver [ Time Frame: 72 weeks ]
    To evaluate the CV events in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo
  • Changes in liver enzymes [ Time Frame: 72 weeks ]
    To evaluate liver enzymes in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo
  • Changes in the noninvasive markers of fibrosis and steatosis [ Time Frame: 72 weeks ]
    To evaluate the noninvasive markers in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo
  • Changes in lipid parameters [ Time Frame: 72 weeks ]
    To evaluate the lipid parameters in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo
  • Variation in body weight [ Time Frame: 72 weeks ]
    To evaluate body weight in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo
  • Biomarkers of endothelial and macrophage dysfunction [ Time Frame: 72 weeks ]
    To evaluate macrophage function in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo
  • Changes in markers of homeostasis of glucose and insulin resistance [ Time Frame: 72 weeks ]
    To evaluate the glucose metabolism in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo
  • Changes in cardiovascular risk profile [ Time Frame: 72 weeks ]
    To evaluate cardiovascular risk profile in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo
  • Changes in quality of life (abbreviated health questionnaire SF-36). [ Time Frame: 72 weeks ]
    To evaluate the following endpoints in patients treated with gastric endoscopic tubulization + lifestyle modification with respect to lifestyle modification / placebo
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Multicenter, Randomized, Controlled and Double-blind Study of Efficacy and Safety of Endoscopic Gastric Tubulization in Patients With Non-alcoholic Steatohepatitis (NASH-APOLLO).
Official Title  ICMJE Multicenter, Randomized, Controlled and Double-blind Study of Efficacy and Safety of Endoscopic Gastric Tubulization in Patients With Non-alcoholic Steatohepatitis (NASH-APOLLO).
Brief Summary

Nonalcoholic steatohepatitis is a growing public health problem affecting over 5% of the population. These patients are at increased risk of cardiovascular and liver-related death and have higher rates of malignancy.

The currently standard of care is weight loss and physical exercise, with histological and analytical improvement in patients achieving a 5-10% reduction in body weight. However, less than 25% of the subjects achieve this goal. In obese patients , restrictive surgical treatments and gastric bypass have been successful in improving the metabolic syndrome, insulin resistance and liver histology.

Currently, less invasive and less costly endoscopic techniques are being developed. These techniques also achieve a gastric restriction with similar results than bariatric surgery. One of these is the OverStitch® system (Apollo Endosurgery, Austin, TX, USA). Our aim is to evaluate the efficacy and safety of this method in the improvement of liver histology in obese patients with nonalcoholic steatohepatitis.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Multicenter, randomized,controlled and double-blind study with two parallel arms, placebo (normal endoscopy and lifestyle modification) or endoscopic gastric tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) and lifestyle modification.
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • Non-Alcoholic Fatty Liver Disease
  • Obesity
Intervention  ICMJE
  • Device: Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA)
    This endoscopic technique is defined as a gastric restriction by means of sutures of the entire gastric wall, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
  • Behavioral: Lifestyle modification
    Hypocaloric diet and moderate physical exercise
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    Diagnostic upper endoscopy plus lifestyle modification.
    Intervention: Behavioral: Lifestyle modification
  • Active Comparator: Treatment
    Endoscopic gastric tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) plus lifestyle modification.
    Interventions:
    • Device: Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA)
    • Behavioral: Lifestyle modification
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 1, 2018)
40
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2020
Estimated Primary Completion Date December 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Men or women aged between 18 and 75 years (inclusive) at the time of the first screening visit.
  2. They must provide signed written informed consent and agree to comply the study protocol
  3. Body mass index> 30 kg / m².
  4. Histological confirmation of steatohepatitis in a diagnostic liver biopsy (biopsy obtained in the 6 months prior to randomization or during the selection period) with at least a score of 1 in each component of the NAS score (steatosis with a score of 0 to 3, degeneration by ballooning with a score of 0 to 2 and lobular inflammation with a score of 0 to 3) and fibrosis of 0 to <4, according to the staging system of CRN fibrosis on NASH.
  5. NAS score ≥ 4.
  6. For patients without fibrosis or with stage 1 fibrosis, the NAS score≥5 and one of the following conditions (metabolic syndrome (definition NCEP ATP III), DM type II, HOMA-IR> 6).
  7. The liver biopsy should have been done with a 16 G trucut needle and the minimum size should be 25 mm.

Exclusion Criteria:

  1. Known heart failure (Grade I to IV of the classification of the New York Heart Association).
  2. History of effective bariatric surgery in the 5 years prior to selection.
  3. Patients with a history of clinically significant acute cardiac event in the 6 months prior to selection, such as: acute cardiovascular event, cerebrovascular accident, transient ischemic attack, or coronary heart disease (angina pectoris, myocardial infarction, revascularization procedures).
  4. Weight loss of more than 5% in the 6 months prior to randomization.
  5. Liver cirrhosis.
  6. Non-cirrhotic portal hypertension.
  7. Recent or current background of significant consumption of alcoholic beverages (<5 years). In the case of men, significant consumption is usually defined as more than 30 g of pure alcohol per day. In the case of women, it is usually defined as more than 20 g of pure alcohol per day.
  8. Esophagogastric varices.
  9. Hepatocellular carcinoma
  10. Portal thrombosis.
  11. Pregnancy.
  12. Refusal to give informed consent.
  13. Any medical condition that could reduce life expectancy to less than 2 years, including known cancers.
  14. Signs of any other unstable or clinically significant immunological, endocrine, hematological, gastrointestinal, neurological, neoplastic or psychiatric disease without treatment.
  15. Instability or mental incompetence, so that the validity of the informed consent or the ability to comply with the study are uncertain.

    In addition to the above criteria, the patient must not present any of the following biological exclusion criteria:

  16. Antibodies positive for the human immunodeficiency virus.
  17. Aspartate aminotransferase (AST) and / or ALT> 10 x upper limit of normal (ULN).
  18. Total bilirubin> 25 μmol / l (1.5 mg / dl).
  19. Standardized international index> 1.4.
  20. Platelet count <100 000 / mm3.
  21. Serum creatinine levels> 135 μmol / l (> 1.53 mg / dl) in men and> 110 μmol / l (> 1.24 mg / dl) in women.
  22. Significant renal disease, including nephritic syndrome, chronic kidney disease (patients with markers of hepatic injury or estimated glomerular filtration rate [eGFR] of less than 60 ml / min / 1.73 m2). If an abnormal value is obtained at the first screening visit, the eGFR measurement may be repeated before randomization within the following time frame: minimum 4 weeks after the initial test and maximum 2 weeks before the expected randomization. An abnormal repeated eGFR (less than 60 ml / min / 1.73 m2) leads to exclusion from the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Jose Luis Calleja, Prof +34911916000 ext 417175 joseluis.calleja@uam.es
Contact: Javier Abad, MD +34650814289 jabad@salud.madrid.org
Listed Location Countries  ICMJE Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03426111
Other Study ID Numbers  ICMJE PI17-00499
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Jose Luis Calleja, Puerta de Hierro University Hospital
Study Sponsor  ICMJE Puerta de Hierro University Hospital
Collaborators  ICMJE
  • Hospital Universitario Ramon y Cajal
  • Hospital Universitario Marqués de Valdecilla
  • Hospitales Universitarios Virgen del Rocío
Investigators  ICMJE Not Provided
PRS Account Puerta de Hierro University Hospital
Verification Date December 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP